This broad toxicity appears to greatly contribute to the high “anti-cancer cell activity” that is observed with this compound and clearly contrasts to the KRAS mutant cancer cell line selectivity seen with calmidazolium and 1 (Figure 6B and Supplementary Figures 6A–E). The gene discussed is KRAS; the disease is cancer.